
  
    
      
        Background_NNP
        A_DT causal_NN association_NN between_IN squamous_JJ cell_NN carcinoma_NN
        arising_VBG in_IN the_DT head_NN and_CC neck_NN region_NN (_( HNSCC_NNP )_) and_CC exposure_NN to_TO
        tobacco_NN and_CC alcohol_NN is_VBZ well_RB established_VBN [_NN 1_CD 2_CD 3_CD ]_NN ._.
        However_RB ,_, 10_CD -_: 15_CD %_NN HNSCC_NNP occur_VB in_IN patients_NNS without_IN any_DT
        antecedent_NN history_NN of_IN tobacco_NN or_CC alcohol_NN exposure_NN [_NN 4_CD 5_CD ]_NN ._.
        Several_JJ studies_NNS have_VBP suggested_VBN that_IN these_DT patients_NNS have_VBP a_DT
        divergent_JJ clinical_JJ course_NN compared_VBN to_TO patients_NNS with_IN tobacco_NN
        associated_VBN HNSCC_NNP ,_, which_WDT may_MD be_VB a_DT reflection_NN of_IN differences_NNS
        in_IN the_DT genetic_JJ composition_NN [_NN 4_CD 5_CD 6_CD ]_NN ._. Empiric_NNP evidence_NN
        suggesting_VBG that_IN non-smokers_JJ may_MD respond_VB differently_RB to_TO
        carcinogenic_JJ insults_NNS is_VBZ offered_VBN in_IN a_DT report_NN by_IN Schantz_NNP et_CC
        al_NN ._. ,_, showing_VBG the_DT highest_JJS levels_NNS of_IN chromosomal_NN sensitivity_NN
        in_IN lymphocytes_NNS after_IN exposure_NN to_TO the_DT clastogen_NN bleomycin_NN in_IN
        HNSCC_NNP patients_NNS who_WP were_VBD non-smokers_JJ [_NN 7_CD ]_NN ._. Relatively_RB few_JJ
        studies_NNS have_VBP directly_RB investigated_VBN the_DT impact_NN of_IN
        tobacco_NN /_NN alcohol_NN exposure_NN on_IN the_DT genetic_JJ composition_NN of_IN
        HNSCC_NNP ._. Amplification_NNP and_CC expression_NN of_IN cyclin_NN D_NNP 1_CD ,_, p_NN 53_CD
        mutation_NN and_CC deletions_NNS of_IN 3_CD p_NN ,_, 5_CD q_NN ,_, and_CC 9_CD p_NN 21_CD are_VBP suggested_VBN to_TO
        be_VB influenced_VBN by_IN the_DT degree_NN of_IN tobacco_NN exposure_NN [_NN 4_CD 6_CD 8_CD ]_NN ._.
        The_DT largest_JJS effort_NN on_IN this_DT topic_NN has_VBZ been_VBN reported_VBN by_IN Koch_NNP
        and_CC colleagues_NNS ,_, who_WP found_VBD significantly_RB higher_JJR rates_NNS of_IN p_NN 53_CD
        mutation_NN and_CC loss_NN of_IN heterozygosity_NN at_IN 3_CD p_NN ,_, 4_CD q_NN ,_, and_CC 11_CD q_NN as_IN
        part_NN of_IN allelotyping_VBG analysis_NN of_IN 10_CD individual_JJ loci_NN [_NN 4_CD ]_NN ._.
        No_DT studies_NNS have_VBP utilized_JJ true_JJ genome-wide_JJ evaluative_JJ
        measures_NNS to_TO analyze_VB the_DT impact_NN of_IN carcinogen_NN exposure_NN on_IN
        the_DT accumulated_VBN chromosomal_NN abnormalities_NNS in_IN HNSCC_NNP ._.
        Comparative_NNP genomic_JJ hybridization_NN (_( CGH_NNP )_) ,_, originally_RB
        described_VBN by_IN Kallionemi_NNP in_IN 1992_CD ,_, is_VBZ an_DT ideal_JJ screening_NN
        measure_NN ,_, allowing_VBG the_DT simultaneous_JJ detection_NN of_IN gains_NNS ,_,
        losses_NNS and_CC amplifications_NNS in_IN genetic_JJ information_NN in_IN an_DT
        individual_JJ tumor_NN [_NN 9_CD ]_NN ._. In_IN addition_NN ,_, several_JJ authors_NNS have_VBP
        used_VBN the_DT total_JJ number_NN of_IN chromosomal_NN abnormalities_NNS as_IN an_DT
        assessment_NN of_IN genomic_JJ instability_NN [_NN 10_CD ]_NN ._. In_IN this_DT study_NN ,_,
        CGH_NNP analysis_NN showed_VBD the_DT presence_NN of_IN significant_JJ overlap_VB in_IN
        genomic_JJ instability_NN and_CC in_IN the_DT individual_JJ chromosomal_NN
        abnormalities_NNS based_VBN on_IN the_DT degree_NN of_IN tobacco_NN /_NN alcohol_NN
        exposure_NN in_IN HNSCC_NNP ,_, with_IN the_DT exception_NN of_IN
        gains_NNS /_NN amplifications_NNS at_IN 3_CD q_NN and_CC 1_CD p_NN ._.
      
      
        Results_NNS and_CC Discussion_NNP
        The_DT study_NN population_NN was_VBD divided_VBN into_IN 15_CD (_( 21_CD %_NN )_) patients_NNS
        with_IN limited_JJ and_CC 56_CD patients_NNS (_( 79_CD %_NN )_) with_IN a_DT significant_JJ
        tobacco_NN /_NN alcohol_NN exposure_NN history_NN ._. Of_IN the_DT 15_CD patients_NNS in_IN
        low-level_JJ tobacco_NN /_NN alcohol_NN exposure_NN group_NN ,_, 13_CD patients_NNS gave_VBD
        no_DT history_NN of_IN tobacco_NN usage_NN ,_, while_IN 10_CD patients_NNS gave_VBD no_DT
        history_NN of_IN alcohol_NN exposure_NN ._. Of_IN the_DT two_CD patients_NNS with_IN
        tobacco_NN exposure_NN histories_NNS ,_, one_CD gave_VBD a_DT history_NN of_IN smoking_VBG
        less_JJR than_IN 2_CD packs_NNS of_IN cigarettes_NNS in_IN her_PRP$ lifetime_NN and_CC the_DT
        other_JJ had_VBD a_DT history_NN of_IN smoking_NN 0_CD ._. 5_CD pack_NN years_NNS ,_, 51_CD years_NNS
        prior_RB to_TO presentation_NN with_IN cancer_NN ._. Although_IN patients_NNS
        without_IN significant_JJ tobacco_NN /_NN alcohol_NN exposure_NN were_VBD younger_JJR
        in_IN age_NN ,_, there_EX was_VBD no_DT significant_JJ difference_NN in_IN all_DT other_JJ
        clinical_JJ ,_, tumor_NN ,_, treatment_NN and_CC outcome_NN characteristics_NNS
        (_( Table_NNP 1_LS )_) ._. The_DT difference_NN in_IN age_NN based_VBN on_IN the_DT severity_NN of_IN
        tobacco_NN /_NN alcohol_NN exposure_NN has_VBZ been_VBN previously_RB described_VBN [_NN 4_CD
        7_CD ]_NN ._.
        The_DT median_JJ number_NN of_IN copy_NN number_NN abnormalities_NNS was_VBD 9_CD per_IN
        case_NN ,_, ranging_VBG from_IN 0_CD to_TO 27_CD ._. The_DT most_RBS common_JJ sites_NNS for_IN gains_NNS
        were_VBD 1_CD p_NN ,_, 3_CD q_NN ,_, 5_CD p_NN ,_, 6_CD p_NN ,_, and_CC 11_CD q_NN ,_, losses_NNS 3_CD p_NN ,_, 4_CD q_NN ,_, and_CC 13_CD q_NN ,_, and_CC
        amplifications_NNS 3_CD q_NN 25_CD -_: 27_CD ,_, 11_CD q_NN 13_CD and_CC 8_CD q_NN 24_CD -_: qter_NN (_( Figure_NN 1_LS )_) ._.
        These_DT results_NNS are_VBP congruent_NN with_IN those_DT reported_VBN in_IN the_DT
        literature_NN for_IN CGH_NNP analysis_NN of_IN HNSCC_NNP [_NN 11_CD 12_CD 13_CD 14_CD ]_NN ._. The_DT
        level_NN of_IN genomic_JJ instability_NN ,_, measured_VBN by_IN the_DT median_JJ number_NN
        of_IN continuous_JJ copy_NN number_NN changes_NNS by_IN CGH_NNP analysis_NN was_VBD also_RB
        not_RB influenced_VBN by_IN the_DT severity_NN of_IN carcinogen_NN exposure_NN ._.
        These_DT findings_NNS are_VBP in_IN contrast_NN to_TO allelotyping_VBG studies_NNS ,_,
        which_WDT show_VBP higher_JJR rates_NNS of_IN abnormalities_NNS in_IN patients_NNS with_IN
        significant_JJ tobacco_NN /_NN alcohol_NN exposure_NN [_NN 4_CD ]_NN ._. Since_IN tobacco_NN
        is_VBZ known_VBN to_TO cause_VB single_JJ strand_NN breaks_NNS ,_, it_PRP may_MD be_VB aberrant_NN
        repair_NN of_IN these_DT changes_NNS that_WDT is_VBZ detected_VBN by_IN LOH_NNP ,_, which_WDT are_VBP
        below_IN the_DT threshold_NN of_IN detection_NN by_IN CGH_NNP ._.
        Although_IN the_DT total_JJ number_NN and_CC general_JJ pattern_NN of_IN
        abnormalities_NNS were_VBD similar_JJ ,_, the_DT prevalence_NN of_IN individual_JJ
        abnormalities_NNS was_VBD different_JJ based_VBN on_IN the_DT extent_NN of_IN
        tobacco_NN /_NN alcohol_NN exposure_NN as_IN outlined_VBN in_IN Figure_NN 2_CD ._.
        Amplification_NNP at_IN 3_CD q_NN 26_CD -_: 27_CD (_( p_NN =_SYM 0_CD ._. 05_CD )_) and_CC gain_NN of_IN 1_CD p_NN (_( p_NN =_SYM
        0_CD ._. 03_CD )_) were_VBD significantly_RB more_RBR common_JJ in_IN patients_NNS with_IN
        carcinogen_NN exposure_NN ._. A_DT high_JJ prevalence_NN of_IN 3_CD q_NN amplification_NN
        has_VBZ been_VBN reported_VBN in_IN many_JJ studies_NNS on_IN tobacco-associated_JJ
        cancers_NNS ,_, including_VBG those_DT of_IN the_DT lung_NN ,_, cervix_NN and_CC esophagus_JJ
        [_NN 11_CD 13_CD 14_CD 15_CD 16_CD 17_CD ]_NN ._. We_PRP and_CC others_NNS have_VBP shown_VBN that_IN 
        PIK_NNP 3_CD CA_NNP is_VBZ a_DT candidate_NN oncogene_NN at_IN 3_CD q_NN
        in_IN these_DT tumors_NNS [_NN 12_CD 18_CD 19_CD ]_NN ._. Interestingly_RB ,_, PI_NNP 3_CD K_NNP pathway_NN
        has_VBZ been_VBN suggested_VBN to_TO play_VB a_DT role_NN in_IN modulating_VBG the_DT effects_NNS
        of_IN benzopyrene_NN ,_, a_DT tobacco-derived_JJ carcinogen_NN ,_, and_CC its_PRP$
        metabolite_NN ,_,
        anti-_NN 7_CD ,_, 8_CD -_: dihydroxy-_NN 9_CD ,_, 10_CD -_: epoxy-_NN 7_CD ,_, 8_CD ,_, 9_CD ,_, 10_CD -_: terahydrobenzopyrene_NN
        [_NN 20_CD ]_NN ._.
        Although_IN less_RBR frequent_JJ ,_, 1_CD p_NN gains_NNS are_VBP also_RB common_JJ to_TO many_JJ
        tobacco-associated_JJ malignancies_NNS [_NN 11_CD 13_CD 14_CD 15_CD 16_CD ]_NN ._. Work_NN
        by_IN Racz_NNP and_CC colleagues_NNS suggest_VBP that_IN PAX_NNP 7_CD and_CC ENO_NNP 1_CD may_MD be_VB
        candidate_NN oncogenes_NNS in_IN this_DT region_NN [_NN 21_CD ]_NN ._. PAX_NNP 7_CD is_VBZ part_NN of_IN
        a_DT family_NN of_IN transcription_NN factors_NNS known_VBN to_TO be_VB carcinogenic_JJ ._.
        Evidence_NN suggests_VBZ that_DT gain_NN of_IN function_NN in_IN PAX_NNP 7_CD triggers_VBZ
        neoplastic_JJ development_NN by_IN maintaining_VBG cells_NNS in_IN a_DT
        deregulated_VBN ,_, undifferentiated_JJ and_CC proliferative_JJ state_NN ,_, as_IN
        is_VBZ seen_VBN in_IN alveolar_NN rhabdomyosarcomas_NNS ._. Loss_NN of_IN 6_CD p_NN was_VBD an_DT
        event_NN unique_JJ to_TO patients_NNS with_IN no_DT tobacco_NN /_NN alcohol_NN exposure_NN ._.
        This_DT site_NN may_MD contain_VB a_DT factor_NN protecting_VBG cells_NNS from_IN
        tobacco_NN induced_VBD carcinogenesis_NNS ,_, including_VBG genes_NNS such_JJ as_IN
        MSH_NNP 1_CD ,_, a_DT gene_NN involved_VBN in_IN mismatch_NN repair_NN [_NN 22_CD ]_NN ._.
      
      
        Conclusions_NNP
        Several_JJ limitations_NNS must_MD be_VB taken_VBN into_IN account_NN when_WRB
        assessing_VBG this_DT work_NN ._. First_LS ,_, the_DT retrospective_NN nature_NN of_IN the_DT
        data_NNS collection_NN introduces_VBZ inherent_JJ biases_NNS ._. Second_JJ ,_,
        although_IN it_PRP is_VBZ amongst_IN the_DT largest_JJS studies_NNS analyzing_NN of_IN
        genetic_JJ differences_NNS based_VBN on_IN carcinogen_NN exposure_NN ,_, the_DT
        sample_NN size_NN remains_VBZ small_JJ limiting_VBG statistical_JJ power_NN to_TO
        detect_VB existing_VBG differences_NNS ._. Finally_RB ,_, CGH_NNP is_VBZ limited_VBN in_IN
        resolution_NN to_TO copy_VB number_NN abnormalities_NNS >_NN 5_CD Kb_NNP ,_, making_VBG it_PRP
        likely_JJ that_IN smaller_JJR aberrations_NNS may_MD exist_VB that_WDT are_VBP
        influenced_VBN by_IN tobacco_NN /_NN alcohol_NN exposure_NN ._. Taking_VBG the_DT
        limitations_NNS into_IN account_NN ,_, we_PRP identified_VBD no_DT differences_NNS in_IN
        the_DT degree_NN of_IN chromosomal_NN instability_NN and_CC significant_JJ
        overlap_VB in_IN the_DT pattern_NN of_IN chromosomal_NN aberrations_NNS occurring_VBG
        in_IN patients_NNS with_IN HNSCC_NNP divided_VBN by_IN the_DT severity_NN of_IN
        tobacco_NN /_NN alcohol_NN exposure_NN ._. However_RB ,_, several_JJ individual_JJ
        differences_NNS exist_VBP ,_, including_VBG amplification_NN of_IN 3_CD q_NN and_CC gain_NN
        of_IN 1_CD p_NN ,_, which_WDT may_MD represent_VB specific_JJ sites_NNS of_IN damage_NN by_IN
        tobacco_NN /_NN alcohol_NN carcinogens_NNS ._. Further_RB work_NN is_VBZ required_VBN to_TO
        refine_VB the_DT finding_NN of_IN this_DT study_NN and_CC understand_VB its_PRP$
        implications_NNS ._.
      
      
        Methods_NNP
        
          Tissue_NNP aquisition_NN and_CC clinical_JJ information_NN
          Tumor_NNP samples_NNS from_IN patients_NNS undergoing_VBG curative_JJ
          treatment_NN for_IN HNSCC_NNP were_VBD obtained_VBN at_IN time_NN of_IN biopsy_NN or_CC
          surgical_JJ resection_NN in_IN the_DT operating_VBG room_NN ,_, following_VBG
          guidelines_NNS established_VBN by_IN the_DT Institutional_NNP Review_NNP Board_NNP ._.
          Only_RB patients_NNS with_IN previously_RB untreated_JJ HNSCC_NNP were_VBD
          included_VBN in_IN this_DT study_NN ._. All_DT samples_NNS were_VBD analyzed_VBN
          histologically_RB to_TO confirm_VB the_DT presence_NN of_IN >_NN 70_CD %_NN
          carcinoma_NN ._. The_DT study_NN population_NN included_VBD 71_CD patients_NNS
          ranging_VBG in_IN age_NN from_IN 38_CD to_TO 89_CD years_NNS (_( median-_NN 61_CD years_NNS )_) ._.
          There_EX was_VBD a_DT predominance_NN of_IN males_NNS (_( 66_CD %_NN )_) ._. The_DT oral_JJ cavity_NN
          (_( 17_CD %_NN )_) and_CC laryngopharynx_NN (_( 83_CD %_NN )_) were_VBD the_DT most_RBS common_JJ
          primary_JJ sites_NNS ._. Overall_RB ,_, 36_CD (_( 51_CD %_NN )_) patients_NNS were_VBD treated_VBN
          surgically_RB ,_, with_IN adjuvant_NN radiation_NN utilized_JJ for_IN patients_NNS
          with_IN advanced_VBD TNM_NNP stage_NN (_( 4_CD cases_NNS )_) or_CC extracapsular_NN
          extension_NN pathologically_RB identified_VBD in_IN nodal_NN metastasis_NNS
          (_( 2_CD patients_NNS )_) ._. Radiation_NNP alone_RB was_VBD utilized_JJ in_IN 35_CD patients_NNS
          and_CC in_IN combination_NN with_IN chemotherapy_NN in_IN 33_CD patients_NNS ._. The_DT
          median_JJ follow-up_JJ for_IN the_DT study_NN population_NN was_VBD 38_CD months_NNS ,_,
          ranging_VBG from_IN 2_CD -_: 109_CD months_NNS ._.
          Tobacco_NNP usage_NN was_VBD assessed_VBN in_IN pack-years_JJ ,_, defined_VBN by_IN
          the_DT number_NN of_IN packs_NNS of_IN cigarettes_NNS smoked_VBD daily_RB multiplied_VBN
          by_IN the_DT number_NN of_IN years_NNS of_IN active_JJ smoking_NN ._. For_IN the_DT
          purposes_NNS of_IN this_DT analysis_NN ,_, smoking_NN 4_CD hand_NN rolled_VBD
          cigarettes_NNS ,_, 4_CD cigars_NNS ,_, or_CC 4_CD pipes_NNS full_JJ of_IN tobacco_NN was_VBD
          considered_VBN equivalent_JJ to_TO smoking_NN 1_CD pack_NN of_IN industrial_JJ
          cigarettes_NNS ._. Tobacco_NNP usage_NN was_VBD coded_VBN as_IN a_DT dichotomous_JJ
          variable_NN ,_, and_CC was_VBD considered_VBN positive_JJ if_IN a_DT greater_JJR than_IN
          2_CD -_: pack_NN year_NN smoking_NN history_NN was_VBD reported_VBN ._. Alcohol_NN
          consumption_NN was_VBD also_RB recorded_VBN as_IN a_DT dichotomous_JJ variable_NN ,_,
          and_CC was_VBD considered_VBN positive_JJ when_WRB daily_JJ usage_NN of_IN two_CD
          alcohol_NN equivalents_NNS on_IN a_DT daily_JJ basis_NN or_CC binge_NN alcohol_NN
          usage_NN (_( repetitive_JJ use_NN of_IN >_NN 5_CD alcohol_NN equivalents_NNS at_IN a_DT
          single_JJ sitting_VBG )_) was_VBD reported_VBN ._. For_IN the_DT purpose_NN of_IN this_DT
          study_NN ,_, patients_NNS were_VBD divided_VBN into_IN two_CD groups_NNS based_VBN on_IN the_DT
          history_NN of_IN carcinogen_NN exposure_NN ._. Group_NNP 1_CD had_VBD a_DT limited_JJ or_CC
          no_DT history_NN of_IN tobacco_NN and_CC /_NN or_CC alcohol_NN exposure_NN ,_, while_IN
          group_NN 2_CD patients_NNS reported_VBD significant_JJ tobacco_NN and_CC /_NN or_CC
          alcohol_NN exposure_NN ._.
          Outcome_NNP of_IN treatment_NN was_VBD evaluated_VBN on_IN the_DT date_NN of_IN last_JJ
          patient_NN contact_NN by_IN determining_VBG the_DT presence_NN or_CC absence_NN of_IN
          cancer_NN and_CC the_DT vital_JJ status_NN (_( alive_JJ ,_, dead_JJ ,_, or_CC unknown_JJ )_) ._.
          The_DT date_NN and_CC location_NN of_IN the_DT first_JJ recurrence_NN was_VBD
          ascertained_JJ ._. For_IN patients_NNS who_WP died_VBD ,_, the_DT cause_NN of_IN death_NN
          was_VBD determined_VBN from_IN review_NN of_IN the_DT death_NN certificate_NN ,_,
          physicians_NNS '_POS death_NN summary_NN ,_, and_CC /_NN or_CC tumor_NN registry_NN records_NNS ._.
          Disease-free_NNP survival_NN was_VBD determined_VBN as_IN the_DT differences_NNS
          between_IN time_NN zero_CD (_( date_NN of_IN first_JJ treatment_NN )_) and_CC the_DT date_NN
          of_IN first_JJ recurrence_NN ._. Cause-specific_NNP survival_NN was_VBD the_DT
          difference_NN between_IN time_NN zero_CD and_CC the_DT date_NN of_IN death_NN due_JJ to_TO
          cancer_NN ._.
        
        
          Comparative_NNP genomic_JJ hybridization_NN
          CGH_NNP was_VBD performed_VBN using_VBG previously_RB published_VBN methods_NNS [_NN
          11_CD ]_NN ._. Seven_CD to_TO 10_CD separate_JJ metaphases_NNS were_VBD captured_VBN and_CC
          processed_VBN using_VBG the_DT Quantitative_NNP Image_NN Processing_NNP System_NNP
          (_( Quips_VBZ Pathvysion_NNP system_NN ,_, Applied_NNP Imaging_NNP ,_, Santa_NNP Clara_NNP ,_,
          CA_NNP )_) ._. Red_NNP ,_, green_JJ ,_, and_CC blue_JJ fluorescence_NN intensities_NNS were_VBD
          analyzed_VBN for_IN all_DT metaphase_NN spreads_NNS ,_, normalized_JJ to_TO a_DT
          standard_JJ length_NN ,_, and_CC statistically_RB combined_VBN to_TO show_VB the_DT
          red_JJ :_: green_JJ signal_NN ratio_NN and_CC 95_CD %_NN confidence_NN intervals_NNS for_IN
          the_DT entire_JJ chromosome_NN ._. Copy_NNP number_NN changes_NNS were_VBD detected_VBN
          based_VBN on_IN the_DT variance_NN of_IN the_DT red_JJ :_: green_JJ ratio_NN profile_NN
          from_IN the_DT standard_NN of_IN 1_CD ._. Ratio_NNP values_NNS of_IN 1_CD ._. 2_CD and_CC 2_CD ._. 0_CD were_VBD
          defined_VBN as_IN thresholds_NNS for_IN gains_NNS and_CC amplifications_NNS ,_,
          respectively_RB ,_, and_CC losses_NNS were_VBD defined_VBN as_IN ratio_NN of_IN 0_CD ._. 8_CD or_CC
          lower_JJR ._.
        
        
          Statistical_NNP analysis_NN
          Statistical_NNP comparisons_NNS were_VBD performed_VBN using_VBG the_DT JPM_NNP
          software_NN (_( SAS_NNP Institute_NNP ,_, Inc_NNP ._. ,_, Cary_NNP ,_, NC_NNP )_) ._. Descriptive_NNP
          statistics_NNS were_VBD used_VBN to_TO summarize_VB study_NN data_NNS ._. Statistical_NNP
          significance_NN was_VBD accepted_VBN at_IN a_DT two-tailed_JJ p_NN value_NN of_IN less_JJR
          than_IN or_CC equal_JJ to_TO 0_CD ._. 05_CD ._. The_DT p-value_JJ for_IN accepting_VBG
          significance_NN was_VBD not_RB adjusted_VBN for_IN multiple_JJ comparisons_NNS ._.
          Non-parametric_NNP qualitative_JJ and_CC quantitative_JJ comparisons_NNS
          were_VBD performed_VBN using_VBG Fisher_NNP 's_POS exact_JJ test_NN and_CC
          Kruskal-_NNP Wallis_NNP analysis_NN of_IN variance_NN ,_, respectively_RB ._. The_DT
          Chi_NNP square_JJ test_NN was_VBD utilized_JJ for_IN multi-group_JJ ,_, qualitative_JJ
          comparisons_NNS ._. Survival_NNP data_NNS was_VBD censored_VBN for_IN patients_NNS lost_VBD
          to_TO follow-up_JJ ,_, surviving_VBG to_TO the_DT end_NN to_TO the_DT study_NN ,_, or_CC dying_VBG
          of_IN causes_NNS unrelated_JJ to_TO cancer_NN ._. Survival_NNP curves_NNS were_VBD
          generated_VBN using_VBG the_DT Kaplan-_NNP Meier_NNP (_( product-limit_JJ )_) method_NN
          to_TO allow_VB maximum_NN use_NN of_IN censored_VBN observations_NNS ._. Survival_NNP
          comparisons_NNS were_VBD performed_VBN using_VBG the_DT log-rank_JJ test_NN ._.
        
      
      
        Authors_NNP '_'' contributions_NNS
        BS_NNP was_VBD involved_VBN in_IN the_DT conception_NN ,_, planning_NN ,_,
        organization_NN and_CC supervision_NN of_IN the_DT project_NN ._. He_PRP performed_VBD
        comparative_JJ genomic_JJ hybridization_NN experiments_NNS ._. VBW_NNP
        contributed_VBD equally_RB to_TO the_DT completion_NN of_IN all_DT experiments_NNS ._.
        DP_NNP ,_, ARS_NNP ,_, DK_NNP and_CC JPS_NNP assisted_VBN to_TO conception_NN ,_, planning_NN and_CC
        manuscript_NN preparation_NN ._. AP_NNP assisted_VBN with_IN clinical_JJ data_NNS
        collection_NN and_CC statistical_JJ analysis_NN ._. PHR_NNP assisted_VBN with_IN
        comparative_JJ genomic_JJ hybridization_NN analysis_NN and_CC confirmed_VBD
        all_DT cytogenetic_JJ assignments_NNS and_CC was_VBD the_DT co-supervisor_JJ in_IN
        the_DT project_NN ._.
      
    
  
